515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)
| Autor: | Tabernero, J., Yoshino, T., Kim, T.W., Yaeger, R., Desai, J., Wasan, H.S., Van Cutsem, E., Ciardiello, F., Maughan, T., Eng, C., Tie, J., Fernandez, M.E. Elez, Lonardi, S., Usari, T., Hahn, E., Dychter, S., Ferrier, G., Zhang, X., Kopetz, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S435-S436 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|